Hippocratic AI reported rapid expansion across providers, payors, life sciences, and the public sector following its $126 million Series C round at a $3.5 billion valuation. The company cited more than 150 million clinical interactions to date and new partnerships with health systems, national payors, consulting organizations, and public-sector stakeholders, reflecting growing adoption of its safety-focused, non-diagnostic generative AI healthcare agents to support patient engagement, care access, and operational efficiency at scale.
The company also accelerated its life sciences strategy through a collaboration with Boston Consulting Group and the acquisition of Grove AI, strengthening capabilities in clinical trial engagement and optimization under a newly appointed president of life sciences. Additional momentum included expanded work with federal and rural health partners and deeper penetration among U.S. payors, where Hippocratic AI now supports millions of member interactions across use cases such as chronic condition outreach, care navigation, and medication adherence, reinforcing its positioning as a scalable platform across the healthcare ecosystem.